RQ Bio

News

UK's RQ Bio raises $115m for flu prevention drug

RQ Bio has raised $115m for clinical trials of RQB01, a one-shot antibody designed for strain-agnostic protection against seasonal influenza viruses.

News

AstraZeneca buys into startup RQ Bio's COVID antibodies

Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerabl

News

Bispecific antibody firm Ollin raises $330m in bumper round

Ollin has followed its $100m Series A last year with a massive $330m second round that will fund phase 3 trials of its challenger to Roche's Vabysmo.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks